These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 17137506)

  • 1. FGFR1 and WT1 are markers of human prostate cancer progression.
    Devilard E; Bladou F; Ramuz O; Karsenty G; Dalès JP; Gravis G; Nguyen C; Bertucci F; Xerri L; Birnbaum D
    BMC Cancer; 2006 Nov; 6():272. PubMed ID: 17137506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The miR-96 and RARγ signaling axis governs androgen signaling and prostate cancer progression.
    Long MD; Singh PK; Russell JR; Llimos G; Rosario S; Rizvi A; van den Berg PR; Kirk J; Sucheston-Campbell LE; Smiraglia DJ; Campbell MJ
    Oncogene; 2019 Jan; 38(3):421-444. PubMed ID: 30120411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PYGOPUS2 expression in prostatic adenocarcinoma is a potential risk stratification marker for PSA progression following radical prostatectomy.
    Kao KR; Popadiuk P; Thoms J; Aoki S; Anwar S; Fitzgerald E; Andrews P; Voisey K; Gai L; Challa S; He Z; Gonzales-Aguirre P; Simmonds A; Popadiuk C
    J Clin Pathol; 2018 May; 71(5):402-411. PubMed ID: 28924059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early human prostate adenocarcinomas harbor androgen-independent cancer cells.
    Fiñones RR; Yeargin J; Lee M; Kaur AP; Cheng C; Sun P; Wu C; Nguyen C; Wang-Rodriguez J; Meyer AN; Baird SM; Donoghue DJ; Haas M
    PLoS One; 2013; 8(9):e74438. PubMed ID: 24086346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer.
    Hoogland AM; Jenster G; van Weerden WM; Trapman J; van der Kwast T; Roobol MJ; Schröder FH; Wildhagen MF; van Leenders GJ
    Mod Pathol; 2012 Mar; 25(3):471-9. PubMed ID: 22080055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma.
    Cote RJ; Shi Y; Groshen S; Feng AC; Cordon-Cardo C; Skinner D; Lieskovosky G
    J Natl Cancer Inst; 1998 Jun; 90(12):916-20. PubMed ID: 9637141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical expression of minichromosome maintenance complex protein 2 predicts biochemical recurrence in prostate cancer: a tissue microarray and digital imaging analysis-based study of 428 cases.
    Toubaji A; Sutcliffe S; Chaux A; Lecksell K; Hicks J; De Marzo AM; Platz EA; Netto GJ
    Hum Pathol; 2012 Nov; 43(11):1852-65. PubMed ID: 22554381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrence.
    Zhang C; Kallakury BV; Ross JS; Mewani RR; Sheehan CE; Sakabe I; Luta G; Kumar D; Yadavalli S; Starr J; Sreenath TL; Srivastava S; Pollard HB; Eidelman O; Srivastava M; Kasid UN
    Int J Cancer; 2013 Jul; 133(1):31-42. PubMed ID: 23280553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression.
    Saraon P; Cretu D; Musrap N; Karagiannis GS; Batruch I; Drabovich AP; van der Kwast T; Mizokami A; Morrissey C; Jarvi K; Diamandis EP
    Mol Cell Proteomics; 2013 Jun; 12(6):1589-601. PubMed ID: 23443136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of tumor-associated macrophages in the Hexim1 and TGFβ/SMAD pathway, and their influence on progression of prostatic adenocarcinoma.
    Ok Atılgan A; Özdemir BH; Akçay EY; Ataol Demirkan Ö; Tekindal MA; Özkardeş H
    Pathol Res Pract; 2016 Feb; 212(2):83-92. PubMed ID: 26608417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of gene expression in prostate cancer epithelial and interstitial stromal cells using laser capture microdissection.
    Gregg JL; Brown KE; Mintz EM; Piontkivska H; Fraizer GC
    BMC Cancer; 2010 Apr; 10():165. PubMed ID: 20426842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
    Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
    Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities.
    Terry S; El-Sayed IY; Destouches D; Maillé P; Nicolaiew N; Ploussard G; Semprez F; Pimpie C; Beltran H; Londono-Vallejo A; Allory Y; de la Taille A; Salomon DS; Vacherot F
    Oncotarget; 2015 May; 6(14):11994-2008. PubMed ID: 25596738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens.
    De Marzo AM; Knudsen B; Chan-Tack K; Epstein JI
    Urology; 1999 Apr; 53(4):707-13. PubMed ID: 10197845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
    Zhang X; Wang Y; Ning Y
    Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors.
    Wu JD; Odman A; Higgins LM; Haugk K; Vessella R; Ludwig DL; Plymate SR
    Clin Cancer Res; 2005 Apr; 11(8):3065-74. PubMed ID: 15837762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.
    Chuu CP; Kokontis JM; Hiipakka RA; Fukuchi J; Lin HP; Lin CY; Huo C; Su LC; Liao S
    Cancer Sci; 2011 Nov; 102(11):2022-8. PubMed ID: 21781227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of SATB1 is associated with prostate cancer aggressiveness and disease progression.
    Shukla S; Sharma H; Abbas A; MacLennan GT; Fu P; Danielpour D; Gupta S
    PLoS One; 2013; 8(1):e53527. PubMed ID: 23308245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen regulated genes in human prostate xenografts in mice: relation to BPH and prostate cancer.
    Love HD; Booton SE; Boone BE; Breyer JP; Koyama T; Revelo MP; Shappell SB; Smith JR; Hayward SW
    PLoS One; 2009 Dec; 4(12):e8384. PubMed ID: 20027305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of the chromatin remodeler death-domain-associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrence.
    Tsourlakis MC; Schoop M; Plass C; Huland H; Graefen M; Steuber T; Schlomm T; Simon R; Sauter G; Sirma H; Minner S
    Hum Pathol; 2013 Sep; 44(9):1789-96. PubMed ID: 23642739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.